STAA
Price
$17.88
Change
+$0.48 (+2.76%)
Updated
Apr 24 closing price
Capitalization
1.91B
5 days until earnings call
XRAY
Price
$13.71
Change
+$0.43 (+3.24%)
Updated
Apr 24 closing price
Capitalization
6.69B
13 days until earnings call
Ad is loading...

STAA vs XRAY

Header iconSTAA vs XRAY Comparison
Open Charts STAA vs XRAYBanner chart's image
STAAR Surgical
Price$17.88
Change+$0.48 (+2.76%)
Volume$533K
Capitalization1.91B
DENTSPLY SIRONA
Price$13.71
Change+$0.43 (+3.24%)
Volume$2.46M
Capitalization6.69B
STAA vs XRAY Comparison Chart
Loading...
STAA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XRAY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
STAA vs. XRAY commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is STAA is a Buy and XRAY is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (STAA: $17.88 vs. XRAY: $13.71)
Brand notoriety: STAA and XRAY are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: STAA: 47% vs. XRAY: 74%
Market capitalization -- STAA: $1.91B vs. XRAY: $6.69B
STAA [@Medical Specialties] is valued at $1.91B. XRAY’s [@Medical Specialties] market capitalization is $6.69B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

STAA’s FA Score shows that 0 FA rating(s) are green whileXRAY’s FA Score has 1 green FA rating(s).

  • STAA’s FA Score: 0 green, 5 red.
  • XRAY’s FA Score: 1 green, 4 red.
According to our system of comparison, XRAY is a better buy in the long-term than STAA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

STAA’s TA Score shows that 6 TA indicator(s) are bullish while XRAY’s TA Score has 6 bullish TA indicator(s).

  • STAA’s TA Score: 6 bullish, 3 bearish.
  • XRAY’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, XRAY is a better buy in the short-term than STAA.

Price Growth

STAA (@Medical Specialties) experienced а +5.86% price change this week, while XRAY (@Medical Specialties) price change was +6.86% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +4.80%. For the same industry, the average monthly price growth was -6.16%, and the average quarterly price growth was -2.09%.

Reported Earning Dates

STAA is expected to report earnings on Aug 06, 2025.

XRAY is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Medical Specialties (+4.80% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XRAY($6.69B) has a higher market cap than STAA($1.91B). STAA has higher P/E ratio than XRAY: STAA (90.79) vs XRAY (19.23). STAA (-26.389) and XRAY (-27.019) have similar YTD gains . XRAY has higher annual earnings (EBITDA): 249M vs. STAA (33.2M). XRAY has more cash in the bank: 334M vs. STAA (221M). STAA has less debt than XRAY: STAA (35.8M) vs XRAY (2.3B). XRAY has higher revenues than STAA: XRAY (3.97B) vs STAA (322M).
STAAXRAYSTAA / XRAY
Capitalization1.91B6.69B29%
EBITDA33.2M249M13%
Gain YTD-26.389-27.01998%
P/E Ratio90.7919.23472%
Revenue322M3.97B8%
Total Cash221M334M66%
Total Debt35.8M2.3B2%
FUNDAMENTALS RATINGS
STAA vs XRAY: Fundamental Ratings
STAA
XRAY
OUTLOOK RATING
1..100
1413
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
2
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9194
PRICE GROWTH RATING
1..100
8565
P/E GROWTH RATING
1..100
8583
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XRAY's Valuation (2) in the Medical Specialties industry is significantly better than the same rating for STAA (81). This means that XRAY’s stock grew significantly faster than STAA’s over the last 12 months.

XRAY's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as STAA (100). This means that XRAY’s stock grew similarly to STAA’s over the last 12 months.

STAA's SMR Rating (91) in the Medical Specialties industry is in the same range as XRAY (94). This means that STAA’s stock grew similarly to XRAY’s over the last 12 months.

XRAY's Price Growth Rating (65) in the Medical Specialties industry is in the same range as STAA (85). This means that XRAY’s stock grew similarly to STAA’s over the last 12 months.

XRAY's P/E Growth Rating (83) in the Medical Specialties industry is in the same range as STAA (85). This means that XRAY’s stock grew similarly to STAA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
STAAXRAY
RSI
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
47%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
55%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
57%
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
64%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
62%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
73%
Advances
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
58%
Declines
ODDS (%)
Bearish Trend 9 days ago
85%
Bearish Trend 17 days ago
71%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
53%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
81%
View a ticker or compare two or three
Ad is loading...
STAA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XRAY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NEFFX57.241.15
+2.05%
American Funds New Economy F2
BCISX17.210.32
+1.89%
Brown Capital Mgmt Intl All Com Instl
ISCWX80.78N/A
N/A
Voya Multi-Manager International Sm Cp W
TOLIX16.48N/A
N/A
DWS RREEF Global Infrastructure Inst
RSEAX14.93N/A
N/A
Russell Inv US Strategic Equity A